findmyKOL
Clinical trialNCT05768919RecruitingPhase 1/PHASE2Interventional

Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas

SponsorSignPath Pharma, Inc.Enrollment30Glioblastoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The objective of this study is to assess the tolerability, safety, and efficacy of Liposomal Curcumin (LC) in combination with radiotherapy (RT) and Temozolomide (TMZ) in patients with newly diagnosed High-Grade Gliomas (HGG).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Sibley Memorial Hospital

    Washington D.C., District of Columbia, United States

    Benjamin Levy, MDMatthias Holdhoff, MDMichael J Pishvaian, MD, PhDRachel Alexander, MDSolmaz Sahebjam, MD
    Recruiting
  • Johns Hopkins University/johns Hopkins Hospital

    Baltimore, Maryland, United States

    Carlos Romo, MD, PhDDavid Kamson, MD, PhDJaishri Blakeley, MD, PhDJohn Laterra, MD, PhDKarisa Schreck, MD, PhDKristin Redmond, MD, PhDLawrence Kleinberg, MD, PhDMatthias Holdhoff, MD, PhDStuart Grossman, MD, PhD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Treatment Period 1Treatment Period 2Treatment Period 3Treatment Period 4a
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
3 Mar 2023
Primary completion
28 Feb 2026
Completion
31 May 2027
Last update posted
29 Nov 2024
Registered enrollment
30
Registry id
NCT05768919
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.